ライフサイエンスコーパス: Kawasaki disease

1 nderstanding of the late cardiac sequelae of Kawasaki disease.

2 itis syndromes, Henoch-Schonlein purpura and Kawasaki disease.

3 ification of the specific etiologic agent of Kawasaki disease.

4 e routine primary treatment of children with Kawasaki disease.

5 nts in the search for the etiologic agent of Kawasaki disease.

6 , in respiratory secretions of children with Kawasaki disease.

7 st that HCoV-NH infection is associated with Kawasaki disease.

8 rre syndrome, skin blistering syndromes, and Kawasaki disease.

9 tions from a 6-month-old infant with classic Kawasaki disease.

10 ith superantigen-mediated diseases including Kawasaki disease.

11 hogenic illness(1) and appears distinct from Kawasaki disease.

12 ammatory arthritis, rheumatoid arthritis and Kawasaki disease.

13 MRA accurately defines CAA in patients with Kawasaki disease.

14 aphy findings in patients with CAA caused by Kawasaki disease.

15 , and the short- and long-term management of Kawasaki disease.

16 30th anniversary of the first description of Kawasaki disease.

17 the mainstay of the acute phase treatment of Kawasaki disease.

18 nary artery disease attributed to antecedent Kawasaki disease.

19 ts identified with presumed late sequelae of Kawasaki disease.

20 rences classify MIS-C as being distinct from Kawasaki disease.

21 Ten patients with MIS-A presented with Kawasaki disease.

22 essel arteritis are polyarteritis nodosa and Kawasaki disease.

23 p with myocarditis, toxic-shock syndrome and Kawasaki disease.

24 ction and then to controls with pneumonia or Kawasaki disease.

25 record review for all the potential cases of Kawasaki disease.

26 es have examined the Th17/Treg expression in Kawasaki disease.

27 estations similar to toxic shock syndrome or Kawasaki disease.

28 athy, long QT syndrome, commotio cordis, and Kawasaki disease.

29 met American Heart Association criteria for Kawasaki disease.

30 ificantly elevated during the acute phase of Kawasaki disease.

31 standard initial therapy in the treatment of Kawasaki disease.

32 as the top pathway regulated by microRNAs in Kawasaki disease.

33 ion in vasculitis by using a murine model of Kawasaki disease.

34 Diagnoses included single ventricle (74%), Kawasaki disease (14%), and other heart disease (12%).

35 All children had acute Kawasaki disease 4 to 15 years before the PET study.

36 g on samples from 98 patients diagnosed with Kawasaki disease, 86 febrile children (62 viral infectio

37 Kawasaki disease, a systemic vasculitis that affects you

38 th the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of child

39 aneurysms, some children have IVIG-resistant Kawasaki disease and are at increased risk of developing

40 iations between variants within the gene and Kawasaki disease and atrial fibrillation.

41 Here we review the role of platelets in Kawasaki disease and discuss progress in understanding t

42 e of a 5-year-old boy who was diagnosed with Kawasaki disease and followed up by CT coronary angiogra

43 ecretions from 8 (72.7%) of 11 children with Kawasaki disease and from 1 (4.5%) of 22 control subject

44 work, were similar in both the patients with Kawasaki disease and healthy adult volunteers (82 +/- 14

45 still implicated in the aetiopathogenesis of Kawasaki disease and Henoch-Schonlein purpura.

46 common vasculitides of childhood, including Kawasaki disease and Henoch-Schonlein purpura.

47 nia and PET in 10 children with a history of Kawasaki disease and in 10 healthy young adult volunteer

48 aired in children with a previous history of Kawasaki disease and normal epicardial coronary arteries

49 Children with a history of Kawasaki disease and normal epicardial coronary arteries

50 Children with a previous history of Kawasaki disease and normal epicardial coronary arteries

51 Here, we outline the pathophysiology of Kawasaki disease and summarize and discuss the progress

52 tive endocarditis, congestive heart failure, Kawasaki disease and thromboembolism are associated with

53 phenotype overlapping with but distinct from Kawasaki disease and toxic shock syndrome admitted to a

54 l infection, 16 with viral infection, 8 with Kawasaki disease, and 42 controls.

55 eria including systemic lupus erythematosus, Kawasaki disease, and migraines.

56 terial wall of coronary aneurysms long after Kawasaki disease, and myofibroblasts likely play a centr

57 thnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during childhoo

58 seases including toxic shock syndrome (TSS), Kawasaki disease, and sepsis.

59 e neurologic, cutaneous, articular syndrome, Kawasaki disease, and systemic lupus erythematosus to id

60 ildren younger than 6 years of age, treating Kawasaki disease, and treating polyarteritis nodosa, but

61 The vasculopathy of Kawasaki disease appears to be distinct from that of ath

62 challenges associated with the diagnosis of Kawasaki disease are also included.

63 onary aneurysms or regressed aneurysms after Kawasaki disease are at increased risk and require long-

64 Whether patients with Kawasaki disease are at risk of accelerated atherosclero

65 Diagnostic criteria for Kawasaki disease are problematic because many patients w

66 sions of predominant IgA antibodies in acute Kawasaki disease arterial tissue bind to an antigen pres

67 olymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as the association between vari

68 iated bronchial epithelium indicate that the Kawasaki disease-associated antigen localizes to cytopla

69 samples were obtained from 186 children with Kawasaki disease at 24 h before IVIG therapy, followed b

70 art disease, airborne particulate matter and Kawasaki disease, blood lead levels and blood pressure,

71 In a mouse model of Kawasaki disease, BM-derived macrophages preferentially

72 d at high levels in blood samples from acute Kawasaki disease but not adenovirus-infected control pat

73 air of urinary proteins that are elevated in Kawasaki disease but not other febrile illnesses.

74 healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be

75 arteritis that histopathologically resembles Kawasaki disease, but the mechanism remains unclear.

76 The varying background risk of Kawasaki disease by age was adjusted for in both designs

77 The acute vasculitis of Kawasaki disease can result in coronary artery damage an

78 ethods, control intervals, and categories of Kawasaki disease case included.

79 l tissue bind to an antigen present in acute Kawasaki disease ciliated bronchial epithelium and in a

80 ion of cytoplasmic inclusion bodies in acute Kawasaki disease ciliated bronchial epithelium has provi

81 microscopic studies of the antigen in acute Kawasaki disease ciliated bronchial epithelium indicate

82 g and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee organized a writing group to

83 The heterogeneous clinical presentation of Kawasaki disease complicates diagnosis and treatment, hi

84 mittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease of t

85 valuate the algorithm performance using rare Kawasaki Disease datasets.

86 Kawasaki disease diagnosis is not an effective proxy for

87 of infliximab to primary treatment in acute Kawasaki disease did not reduce treatment resistance.

88 et aggregates are increased in children with Kawasaki disease during the acute phase of the disease a

89 epithelium has provided direction for future Kawasaki disease etiology studies.

90 Two recently proposed theories of Kawasaki disease etiology, the toxic shock syndrome toxi

91 dehyde-fixed medium-sized bronchi from acute Kawasaki disease fatalities and analysis of the protein

92 milarities and differences between MIS-C and Kawasaki disease, focusing on their epidemiology, aetiol

93 associated vasculitis, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, Takayasu arterit

94 As children with Kawasaki disease grow up, adult cardiologists are likely

95 Patients with Kawasaki disease had higher levels of plasma IL-17A (25.

96 West Midlands than previously reported, and Kawasaki disease has a higher incidence than previously

97 In the United States, Kawasaki disease has now surpassed acute rheumatic fever

98 istent or remodeled coronary aneurysms after Kawasaki disease have a high rate of complications inclu

99 ternational and multidisciplinary efforts in Kawasaki Disease have resulted in recommendations for it

100 enesis, treatment, and long-term outcomes of Kawasaki disease, highlighting recent publications.

101 se in young adults that can be attributed to Kawasaki disease in childhood, we performed a retrospect

102 immune globulin is an effective therapy for Kawasaki disease in children, and recent data suggest th

103 The number of patients with a diagnosis of Kawasaki disease in early 2020 was 40% lower (259 vs 433

104 ate the syndrome, although the occurrence of Kawasaki disease in epidemics and its resemblance to tox

105 Incidence of Kawasaki disease in Japan is 10 times higher than in the

106 ovision of care, it is important to consider Kawasaki Disease in older demographics especially with u

107 tence and magnitude of any increased risk of Kawasaki disease in the 28 days following PCV13 vaccinat

108 y analysis, there were 43 confirmed cases of Kawasaki disease in the risk interval and 44 in the cont

109 erson-years, the risk estimates of potential Kawasaki disease in the risk interval versus in unexpose

110 Kawasaki disease in the very young infant is also discus

111 He made many relevant discoveries regarding Kawasaki Disease including its treatment with intravenou

112 a cells infiltrate inflamed tissues in acute Kawasaki disease, including the coronary artery, and are

113 Resistance to intravenous immunoglobulin in Kawasaki disease increases the risk of coronary artery a

114 Conclusions and Relevance: Kawasaki disease is a hybrid condition at the junction o

115 Kawasaki disease is a pediatric vasculitis and the leadi

116 Kawasaki disease is a systemic vasculitis of childhood;

117 Kawasaki disease is a vasculitis most commonly afflictin

118 Kawasaki disease is an acute febrile illness and systemi

119 Kawasaki disease is an acute inflammatory process of the

120 Kawasaki disease is an acute systemic vasculitis of chil

121 Kawasaki disease is an acute vasculitis of childhood tha

122 Kawasaki disease is an acute vasculitis of unknown etiol

123 Kawasaki disease is an acute vasculitis that primarily a

124 Kawasaki disease is an acute, self-limited vasculitis of

125 Kawasaki disease is an acute, self-limited vasculitis of

126 Kawasaki disease is an acute, self-limited vasculitis of

127 Our findings provide further evidence that Kawasaki disease is an autoimmune-like disease.

128 The long-term treatment of children with Kawasaki disease is dependent on coronary artery status.

129 A hallmark of Kawasaki disease is increased blood platelet counts and

130 Kawasaki disease is most common in Japan.

131 Indeed, Kawasaki disease is no longer a rare cause of acute coro

132 Kawasaki disease is recognized as the most common cause

133 Kawasaki disease is the leading cause of acquired heart

134 Kawasaki disease is the most common cause of acquired ca

135 th clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n =

136 Up to 25% of patients with untreated Kawasaki disease (KD) and 5% of those treated with intra

137 Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome

138 Kawasaki disease (KD) and multisystem inflammatory syndr

139 by angiography in children with a history of Kawasaki disease (KD) and pediatric heart transplant (TX

140 The clinical and epidemiological features of Kawasaki disease (KD) are consistent with an infectious

141 Human adenovirus (HAdV) infection mimics Kawasaki disease (KD) but can also be detected in KD pat

142 Kawasaki disease (KD) can be associated with high morbid

143 n Diego, CA, USA), we previously showed that Kawasaki Disease (KD) cases cluster temporally in bursts

144 redicting subtle myocardial abnormalities in Kawasaki disease (KD) children with coronary dilatation

145 laboratory inflammatory markers early after Kawasaki disease (KD) diagnosis.

146 Clinical features of Kawasaki disease (KD) display overlap with common pediat

147 bout a quarter of children with new onset of Kawasaki disease (KD) encounter coronary arterial involv

148 Early awareness of Kawasaki disease (KD) helps physicians administer approp

149 Obesity may affect the clinical course of Kawasaki disease (KD) in children and multisystem inflam

150 Kawasaki disease (KD) is a febrile illness of young chil

151 Kawasaki disease (KD) is a leading cause of pediatric he

152 Kawasaki disease (KD) is a multisystem vasculitis that p

153 Kawasaki Disease (KD) is a potentially fatal acute vascu

154 Kawasaki Disease (KD) is a rare acute febrile illness du

155 Kawasaki disease (KD) is a self-limited, systemic vascul

156 Kawasaki disease (KD) is a systemic vasculitis that affe

157 Kawasaki disease (KD) is a vasculitis of young childhood

158 Kawasaki disease (KD) is an acute inflammatory illness m

159 Kawasaki disease (KD) is an acute pediatric vasculitis i

160 Kawasaki disease (KD) is an acute vasculitis of young ch

161 Kawasaki disease (KD) is an acute, inflammatory, and sel

162 Kawasaki disease (KD) is an acute, self-limited vasculit

163 Kawasaki disease (KD) is an enigmatic, self-limited vasc

164 Kawasaki disease (KD) is an inflammatory autoimmune vasc

165 Acute Kawasaki disease (KD) is difficult to distinguish from o

166 Kawasaki disease (KD) is one of the most common vasculit

167 Kawasaki disease (KD) is the leading cause of childhood

168 Kawasaki disease (KD) is the leading cause of pediatric

169 Kawasaki disease (KD) is the most common acquired cardia

170 Kawasaki disease (KD) is the most common cause of acquir

171 In developed nations, Kawasaki disease (KD) is the most common cause of acquir

172 Kawasaki disease (KD) is the most common cause of acquir

173 Kawasaki disease (KD) is the most common cause of acute

174 Kawasaki Disease (KD) is the most common paediatric vasc

175 Importance: Kawasaki disease (KD) is the most recognized vasculitis

176 s of coronary arterial inflammation in acute Kawasaki disease (KD) is unclear.

177 Kawasaki disease (KD) or mucocutaneous lymph node syndro

178 to compare the indices of vascular health in Kawasaki disease (KD) patients to those of control subje

179 entified in ciliated bronchial epithelium of Kawasaki disease (KD) patients using a synthetic antibod

180 , 20 healthy control subjects and 20 classic Kawasaki disease (KD) patients were retrospectively revi

181 The etiology and pathogenesis of Kawasaki disease (KD) remain unknown.

182 Kawasaki disease (KD) shares several clinical features w

183 Kawasaki disease (KD) symptoms significantly overlap wit

184 oglobulin (IVIG) are standard treatments for Kawasaki disease (KD) to reduce coronary artery lesions

185 The sequelae of Kawasaki disease (KD) vary widely with the greatest risk

186 tors potentially influenced the incidence of Kawasaki disease (KD), a self-limited pediatric vasculit

187 ntravenous immunoglobulin (IVIG) response in Kawasaki disease (KD), a vasculitis preferentially affec

188 new condition is heterogenous but resembles Kawasaki disease (KD), a well-known but poorly understoo

189 Kawasaki disease (KD), an acute self-limited febrile ill

190 es, including APS1, IPEX, RAG1/2 deficiency, Kawasaki disease (KD), multisystem inflammatory syndrome

191 range of inflammatory conditions, including Kawasaki disease (KD), multisystem inflammatory syndrome

192 st persistent myocardial abnormalities after Kawasaki disease (KD), the long-term effects on cardiac

193 Kawasaki disease (KD), the most common cause of acquired

194 The etiology of Kawasaki Disease (KD), the most common cause of acquired

195 re is replicated in an independent cohort of Kawasaki disease (KD), the related condition after which

196 The illness resembles Kawasaki disease (KD), with coronary dilatation and aneu

197 thrombosis is the major risk associated with Kawasaki disease (KD).

198 children (MIS-C), partially overlapping with Kawasaki disease (KD).

199 l features with the pre-pandemic syndrome of Kawasaki disease (KD).

200 ukin-1beta (IL-1beta) in the pathogenesis of Kawasaki disease (KD).

201 lobulin (IVIG) is the treatment of choice in Kawasaki disease (KD).

202 th intravenous immunoglobulin for incomplete Kawasaki disease (KD).

203 Patients with Kawasaki disease (kDa) may develop coronary arterial les

204 ysms develop in some untreated children with Kawasaki disease, leading to ischaemic heart disease and

205 The syndrome has been described as a "Kawasaki disease"-like illness and the spectrum of assoc

206 20 for multisystem inflammatory syndrome and Kawasaki disease-like features related to coronavirus di

207 By contrast, Kawasaki disease mainly occurs in children aged under 5

208 specific diagnostic tests and biomarkers for Kawasaki disease make early diagnosis and treatment chal

209 ic pregnancy, encephalitis, intussusception, Kawasaki disease, mastoiditis, myocarditis, necrotizing

210 5%) of 22 control subjects (children without Kawasaki disease matched by age and the time the specime

211 athy-like kidney disease in miR-23b(-/-) and Kawasaki disease mice is likely mediated through TRDMT1-

212 Collection Center) cell wall extract-induced Kawasaki disease mice were treated with 5-azacytidine.

213 athy-like kidney disease in miR-23b(-/-) and Kawasaki disease mice, while mesangial IgA and C3 deposi

214 ng syndromes, such as pneumonia (N = 17) and Kawasaki disease (N = 13), and found a distinct three-pr

215 (c.742+871A>G) allele-positive patients with Kawasaki disease (n = 208) and 1 patient with idiopathic

216 have been published, in Behcet's disease and Kawasaki disease; none of the genes identified in these

217 an association between PCV13 vaccination and Kawasaki disease onset in the 4 weeks after vaccination

218 e confirmed, our findings suggest a model of Kawasaki disease pathogenesis whereby miR-145 modulates

219 scovery of microRNAs that may participate in Kawasaki disease pathogenesis.

220 A recent study in a Japanese population of Kawasaki disease patients at high risk for IVIG resistan

221 Consequently, only recently have Kawasaki disease patients reached adulthood and come to

222 The Kawasaki disease patients were previously classified int

223 taneous intervention have been used to treat Kawasaki disease patients who develop myocardial ischemi

224 use IVIG as a second-line therapy for those Kawasaki disease patients who have persistent or recrude

225 4 TEs occurred (2.8%; 2 strokes and 2 of 33 Kawasaki disease patients with coronary artery thrombose

226 l extracellular vesicles isolated from acute Kawasaki disease plasma samples.

227 ribe a case of an adolescent presentation of Kawasaki Disease presenting with a predominantly cholest

228 avenous immunoglobulin and aspirin) in acute Kawasaki disease reduces the rate of treatment resistanc

229 nisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abn

230 this cohort study, analysis of International Kawasaki Disease Registry (IKDR) data on contemporaneous

231 The cause of Kawasaki disease remains unknown and this presents many

232 The cause of Kawasaki disease remains unknown, but fortunately intrav

233 Therapy for Kawasaki disease resistant to intravenous immune globuli

234 he FDA decided to initiate a larger study of Kawasaki disease risk following PCV13 vaccination in the

235 In patients with Kawasaki disease, serial evaluation of the distribution

236 A history of antecedent Kawasaki disease should be sought in all young adults wh

237 e RNA profiles may be used as biomarkers for Kawasaki disease stratification and offer new insight in

238 the utility of cell-free RNA to characterize Kawasaki disease subgroups at a molecular level.

239 The 5th International Kawasaki Disease Symposium was held in May 1995 in Fukuo

240 ere significantly lower in the patients with Kawasaki disease than in the control subjects (263 +/- 6

241 y resistance was higher in the patients with Kawasaki disease than in the healthy adult volunteers (3

242 flow reserve were lower in the patients with Kawasaki disease than in the healthy young adult volunte

243 Kawasaki disease, the most common cause of acquired hear

244 nsure safety review that identified cases of Kawasaki disease through adverse event reporting.

245 in a subset of macrophages in acute inflamed Kawasaki disease tissues.

246 cts (age 10 to 25 years) with known CAA from Kawasaki disease underwent coronary MRA using a free-bre

247 may be a potential therapeutic candidate for Kawasaki disease vasculitis and other IL-1 mediated infl

248 telets in amplifying inflammation related to Kawasaki disease vasculitis and therapeutic strategies t

249 The use of experimental mouse models of Kawasaki disease vasculitis has considerably improved ou

250 The estimated annual incidence of Kawasaki disease was 5.5 per 100000 in children younger

251 Kawasaki disease was associated with higher IL-17A and I

252 PURPOSE OF REVIEW: Kawasaki disease was first described in Japanese in 1967

253 le association between HCoV-NH infection and Kawasaki disease, we conducted a case-control study.

254 croRNAs play in modifying gene expression in Kawasaki disease, we studied microRNAs from whole blood

255 d of 12 patients with acute and convalescent Kawasaki disease were analyzed by sequencing of small RN

256 Potential cases of Kawasaki disease were identified by first-in-365-days In

257 ng our DP TDT in a real dataset in analyzing Kawasaki disease with 187 families and 906 SNPs.

258 Treatment of acute Kawasaki disease with intravenous immune globulin and as

259 a family-based allelic association study for Kawasaki Disease, with data hosted in three different co

260 ugate vaccine (PCV13), comparing the risk of Kawasaki disease within 28 days of PCV13 vaccination wit